The merger is expected to close early in the second quarter of 2011, the companies said in a press statement.
Each Genzyme shareholder also will receive one contingent value right for each share they own, entitling the holder to receive additional cash payments if specified milestones related to Lemtrada, Cerezyme and Fabrazyme are achieved, French drugmaker Sanofi said.
"This agreement with Genzyme is both consistent with our long-term strategy and creates significant long-term value for our shareholders," said Christopher Viehbacher, Sanofi CEO. "This transaction will create a meaningful new growth platform for Sanofi-Aventis while expanding our footprint in biotechnology."Sanofi said It expects the deal to be accretive in the first year following its completion. Genzyme shares closed Tuesday at $74.30 on reports the deal was imminent. -- Written by Joseph Woelfel
>To contact the writer of this article, click here: Joseph Woelfel >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV